Physician profile
Christopher Scott
NPI 1205591294
$4,123.79
in general payments reported to CMS, 2019-2025
29 companies · $1,909 in 2025
The $1,909 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $28.59 · 2024: $2,186 · 2025: $1,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,232 · Travel and Lodging: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,232.04 |
| Travel and Lodging | $891.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,952.40 | 2024-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Neurocrine Biosciences, INC. | $296.98 | 2024-2025 | Ingrezza |
| Ucb, INC. | $296.32 | 2024-2025 | Briviact, Fintepla, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $269.74 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Eisai INC. | $175.07 | 2024-2025 | |
| Sk Life Science, INC. | $145.04 | 2024-2025 | |
| Lundbeck LLC | $123.58 | 2024-2025 | Vyepti |
| Ge Healthcare | $94.40 | 2024-2025 | |
| Abbvie INC. | $83.32 | 2024-2025 | |
| Pfizer INC. | $81.46 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $68.68 | 2025 | Xeomin |
| Neurelis, INC. | $46.44 | 2025 | Valtoco |
| Argenx US, INC. | $44.02 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Harmony Biosciences LLC | $42.49 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $39.64 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $38.83 | 2025 | Ultomiris |
| Genentech USA, INC. | $35.98 | 2025 | Ocrevus Zunovo |
| Lilly USA, LLC | $31.01 | 2024 | Reyvow, Emgality, Kisunla |
| Biogen, INC. | $30.31 | 2025 | Tysabri, Vumerity, Skyclarys |
| Ethicon US, LLC | $28.59 | 2023 | Enseal X1, Echelon; Endopath, Echelon Endopath |
| Amgen INC. | $27.65 | 2024 | Uplizna |
| C2n Diagnostics, LLC | $25.68 | 2025 | Precivityad2 |
| Octapharma USA, INC. | $25.02 | 2025 | Panzyga |
| Amneal Pharmaceuticals LLC | $24.38 | 2024 | Crexont |
| Astrazeneca Pharmaceuticals Lp | $24.06 | 2025 | Wainua |
| Inspire Medical Systems, INC. | $21.19 | 2025 | Inspire |
| Aucta Pharmaceuticals, INC. | $20.64 | 2025 | Motpoly Xr |
| Kyowa Kirin, INC. | $16.37 | 2024 | Nourianz |
| Tg Therapeutics, INC. | $14.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.